Vincristine - CAS 2068-78-2
Catalog number: 2068-78-2
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C46H58N4O14S
Molecular Weight:
923.04
COA:
Inquire
Targets:
Microtubule/Tubulin
Description:
Vincristine is an inhibitor of polymerization of microtubules by binding to tubulin with IC50 of 32 μM.
Purity:
>98%
Synonyms:
Leurocristine
MSDS:
Inquire
InChIKey:
AQTQHPDCURKLKT-PNYVAJAMSA-N
InChI:
InChI=1S/C46H56N4O10.H2O4S/c1-7-42(55)22-28-23-45(40(53)58-5,36-30(14-18-48(24-28)25-42)29-12-9-10-13-33(29)47-36)32-20-31-34(21-35(32)57-4)50(26-51)38-44(31)16-19-49-17-11-15-43(8-2,37(44)49)39(60-27(3)52)46(38,56)41(54)59-6;1-5(2,3)4/h9-13,15,20-21,26,28,37-39,47,55-56H,7-8,14,16-19,22-25H2,1-6H3;(H2,1,2,3,4)/t28-,37-,38+,39+,42-,43+,44+,45-,46-;/m0./s1
Canonical SMILES:
CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O
1.Bendamustine plus rituximab versus R-CHOP as first-line treatment for patients with indolent non-Hodgkin's lymphoma: evidence from a multicenter, retrospective study.
Mondello P1,2,3, Steiner N4, Willenbacher W4, Wasle I4, Zaja F5, Zambello R6, Visentin A6, Mauro E7, Ferrero S8, Ghione P8, Pitini V9, Cuzzocrea S10, Mian M4,11. Ann Hematol. 2016 Apr 22. [Epub ahead of print]
The optimal first-line treatment for advanced low-grade non-Hodgkin lymphomas (LG-NHL) is still highly debated. Recently, the StiL and the BRIGHT trials showed that the combination of rituximab and bendamustine (R-B) is non-inferior to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with a better toxicity profile. Utilizing a retrospective analysis, we compared the efficacy and safety of both regimens in clinical practice. From November 1995 to January 2014, 263 LG-NHL patients treated with either R-B or R-CHOP were retrospectively assessed in seven European cancer centers. Ninety patients were treated with R-B and 173 with R-CHOP. Overall response rate was 94 and 92 % for the R-B and the R-CHOP group, respectively. The percentage of complete response was similar for both groups (63 vs. 66 % with R-B and R-CHOP, respectively; p = 0.8). R-B was better tolerated and less toxic than R-CHOP. The median follow-up was 6.
2.Mandibular melanotic neuroectodermal tumor of infancy: a role for neoadjuvant chemotherapy.
Maroun C1, Khalifeh I2, Alam E3, Akl PA3, Saab R4, Moukarbel RV5. Eur Arch Otorhinolaryngol. 2016 Apr 23. [Epub ahead of print]
Melanotic Neuroectodermal Tumor of Infancy (MNTI) is a rare, locally aggressive neoplasm with a predilection for the head and neck area, most commonly occurring in the maxilla. The vast majority of treatment modalities for all cases of MNTI to date have involved surgical intervention only, with just 9.6 % involving some sort of chemotherapy, radiotherapy, or a combination of the prior mentioned modalities. There is very limited information available regarding the use of neoadjuvant chemotherapy, due to its rare nature. In this report, a 4 month old girl presented to our clinic with a chief complaint of a large oral mass of about 2.5 months in duration. Intraoral examination showed an oral mass arising from the lingual aspect of inferior alveolar ridge with extensive mandibular invasion. The patient received three cycles of vincristine, Adriamycin, and cyclophosphamide as neodajuvant therapy. Upon completion, the tumor had decreased significantly in size.
3.Successful Propranolol Treatment of a Kaposiform Hemangioendothelioma Apparently Resistant to Propranolol.
Filippi L1, Tamburini A2, Berti E1, Perrone A3, Defilippi C3, Favre C2, Calvani M2, Della Bona ML4, la Marca G4, Donzelli G1. Pediatr Blood Cancer. 2016 Apr 21. doi: 10.1002/pbc.25979. [Epub ahead of print]
A newborn with unresectable kaposiform hemangioendothelioma associated with Kasabach Merritt phenomenon, unresponsive to vincristine and prednisone, received second-line treatment with propranolol at a dose of 2 mg/kg/day, starting at 2 months of life and continued for 13 months. There was only slight reduction in tumor mass, but measurement of propranolol levels showed extremely low plasma concentrations. The propranolol dose was progressively increased to 3.5 mg/kg/day, leading to a substantial increase in plasma levels associated with clinically relevant tumor reduction. This case highlights the importance of relating propranolol dose to its plasma concentration before considering the treatment ineffective for this vascular tumor.
4.Prognostic impact of sarcopenia in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.
Go SI1, Park MJ2, Song HN1, Kim HG3, Kang MH1, Lee HR1, Kim Y1, Kim RB4, Lee SI5, Lee GW3. J Cachexia Sarcopenia Muscle. 2016 Apr 12. doi: 10.1002/jcsm.12115. [Epub ahead of print]
BACKGROUND: Sarcopenia is known to be related to an increased risk of chemotherapy toxicity and to a poor prognosis in patients with malignancy. We assessed the prognostic role of sarcopenia in patients with diffuse large B-cell lymphoma (DLBCL).
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Microtubule/Tubulin Products


CAS 41179-33-3 CMPD-1

CMPD-1
(CAS: 41179-33-3)

CMPD-1, also called MK2a Inhibitor, inhibits tubulin polymerisation. It inhibit p38α-mediated MK2a phosphorylation (apparent Ki = 330 nM).

CAS 1228105-51-8 DM1-SMCC

DM1-SMCC
(CAS: 1228105-51-8)

This active molecular is DM1 with a linker SMCC that can react with antibody to make antibody drug conjugate. DM1 is an antibody-conjugatable maytansinoid that ...

CAS 125317-39-7 Vinorelbine ditartrate

Vinorelbine ditartrate
(CAS: 125317-39-7)

Vinorelbine ditartrate, whose base is Vinorelbine, is a selective mitotic microtubule antagonist. It inhibits proliferation of Hela cells (IC50= 1.25 nM) and s...

AADvac-1

AADvac-1 is an active vaccine designed to raise antibodies against pathological tau protein (the primary constituent of neurofibrillary pathology in AD). These ...

CAS 945771-74-4 BNC-105

BNC-105
(CAS: 945771-74-4)

BNC105 is a novel compound being developed by Bionomics as a Vascular Disrupting Agent (VDA) for treatment of cancer. VDAs are drugs that disrupt the blood vess...

CAS 90332-66-4 7-xylosyltaxol

7-xylosyltaxol
(CAS: 90332-66-4)

7-xylosyltaxol is a taxol (Paclitaxel) derivative, which binds to tubulin and inhibits the disassembly of microtubules.

CAS 194468-36-5 Vinflunine ditartrate

Vinflunine ditartrate
(CAS: 194468-36-5)

Vinflunine, a semisynthetic derivative of Vinorelbine, is the first fluorinated microtubule inhibitor belonging to the Vinca alkaloids family endowed with uniqu...

Dolastatin 10 trifluoroacetate

Dolastatin 10 trifluoroacetate inhibits tubulin polymerization and induces tubulin aggregation in vitro.

Chemical Structure

CAS 2068-78-2 Vincristine

Quick Inquiry

Verification code

Featured Items